loader
Please Wait
Applying Filters...
menu
    • menu

    Technical details about Naporafenib, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Naporafenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Lxh254, 1800398-38-2, Lxh-254, Lxh254 free base, N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, Pan-raf inhibitor lxh254
    Molecular Formula
    C25H25F3N4O4
    Molecular Weight
    502.5  g/mol
    InChI Key
    UEPXBTCUIIGYCY-UHFFFAOYSA-N
    FDA UNII
    15JL80DG6H
    Naporafenib is an orally available inhibitor of all members of the serine/threonine protein kinase Raf family, with potential antineoplastic activity. Upon administration, naporafenib binds to Raf proteins and inhibits Raf-mediated signal transduction pathways. This inhibits proliferation of Raf-overexpressing tumor cells. Raf protein kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are upregulated in a variety of cancer cell types. They play key roles in tumor cell proliferation and survival.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide
    2.1.2 InChI
    InChI=1S/C25H25F3N4O4/c1-16-2-3-19(30-24(34)17-4-5-29-21(12-17)25(26,27)28)15-20(16)18-13-22(32-6-9-35-10-7-32)31-23(14-18)36-11-8-33/h2-5,12-15,33H,6-11H2,1H3,(H,30,34)
    2.1.3 InChI Key
    UEPXBTCUIIGYCY-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C(C=C(C=C1)NC(=O)C2=CC(=NC=C2)C(F)(F)F)C3=CC(=NC(=C3)OCCO)N4CCOCC4
    2.2 Other Identifiers
    2.2.1 UNII
    15JL80DG6H
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Lxh254

    2.3.2 Depositor-Supplied Synonyms

    1. Lxh254

    2. 1800398-38-2

    3. Lxh-254

    4. Lxh254 Free Base

    5. N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

    6. Pan-raf Inhibitor Lxh254

    7. Naporafenib [inn]

    8. 15jl80dg6h

    9. 1800398-38-2 (free Base)

    10. N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide

    11. 4-pyridinecarboxamide, N-(3-(2-(2-hydroxyethoxy)-6-(4-morpholinyl)-4-pyridinyl)-4-methylphenyl)-2-(trifluoromethyl)-)-

    12. N-(3-(2-(hydroxyethoxy)-6-(morpholin-4-yl) Pyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)pyridine-4-carboxamide

    13. N-{3-[2-(2-hydroxyethoxy)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl}-2-(trifluoromethyl)pyridine-4-carboxamide

    14. Lxh 254

    15. K81

    16. Unii-15jl80dg6h

    17. Naporafenib [who-dd]

    18. Chembl4583691

    19. Lxh 254 [who-dd]

    20. Schembl16094629

    21. Bdbm88120

    22. Gtpl10658

    23. Bcp29080

    24. Ex-a1846

    25. Nsc807047

    26. S8745

    27. Akos037648965

    28. At23218

    29. Nsc-807047

    30. Compound 15 [pmid: 31059256]

    31. Ac-36207

    32. Bl166445

    33. Bs-16133

    34. Hy-112089

    35. Cs-0043317

    36. Example 1156 [wo2014151616a1]

    37. A16841

    38. Us9694016, 1156

    2.4 Create Date
    2015-02-13
    3 Chemical and Physical Properties
    Molecular Weight 502.5 g/mol
    Molecular Formula C25H25F3N4O4
    XLogP33.2
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count10
    Rotatable Bond Count7
    Exact Mass502.18278978 g/mol
    Monoisotopic Mass502.18278978 g/mol
    Topological Polar Surface Area96.8 Ų
    Heavy Atom Count36
    Formal Charge0
    Complexity709
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)